Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng differentiation herbal formula is a Traditional Chinese Medicine (TCM) therapeutic approach developed by Longhua Hospital, Shanghai University of Traditional Chinese Medicine. It is designed for the management of stage IIIA non-small cell lung cancer (NSCLC) following surgical resection. The formula is based on the 'Fuzheng' principle, which focuses on strengthening the body's vital energy (Qi) and immune function to prevent cancer recurrence and metastasis. As a 'differentiation' formula, the specific herbal composition is individualized for each patient according to TCM diagnostic patterns (syndromes). It is typically administered as an adjuvant therapy alongside standard treatments like chemotherapy and radiotherapy to enhance efficacy and reduce treatment-related toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuzheng differentiation herbal formula.